Evidence map›Paper›PMID 39096371›Full record

ArticleAnnals of hematology2024

Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report.

E Tamellini, C Simio, A Bernardelli, I Ferrarini, A Vatteroni, A Moioli, V Macaluso, E Marchetti, I Tanasi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

E Tamellini *Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy. edoardo.tamellini@univr.it.
C Simio *Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
A BernardelliHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
I FerrariniDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
A VatteroniDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
A MoioliDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
V MacalusoDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
E MarchettiDepartment of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
I Tanasi *Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy. ilaria.tanasi@aovr.veneto.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combined therapy with venetoclax and hypomethylating agents has significantly improved the outcome of unfit patients ineligible for intensive chemotherapy. A recently published exploratory analysis of the VIALE-A trial reported that up to 51% of patients achieving remission survived more than 2 years. These data along with those from reallife settings, lead to questioning how long it is appropriate to continue treatment in long-term survivors. Accordingly, recent retrospective studies suggested the feasibility of suspending therapy in selected patients while maintaining prolonged responses. Also, these studies showed that retreatment may induce a second remission in almost a third of patients. We report the case of a patient who received salvage therapy with venetoclax and azacytidine, that was discontinued few cycles after blasts clearance because of severe hematological toxicity. Despite suspension, he maintained a sustained response lasting almost one year and was successfully retreated with the same combination when a second relapse occurred.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteRemission InductionSulfonamidesAgedHumansMaleMiddle AgedRecurrenceSalvage TherapyAzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclaxAcute myeloid leukemiaAzacytidineRechallengeRetreatmentTreatment-free remissionVenetoclax

Identifiers

PMID39096371
PMCPMC11512829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.